Anthrax prophylaxis: Recent advances and future directions

Frontiers in Microbiology

Volumn 6, Issue SEP, 2015, Pages

  Williamson, E Diane ^a   Dyson, Edward Hugh ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Adenylate cyclase; Anthrax; MAP kinase; Pathogenesis; Prophylaxis; Therapy; Toxemia

Indexed keywords

ADENYLATE CYCLASE; ANTHRAX VACCINE; ANTIGEN; EDEMA FACTOR; MONOCLONAL ANTIBODY; POLYGLUTAMIC ACID; PROTECTIVE ANTIGEN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTHRAX; ANTIBIOTIC THERAPY; BACILLUS ANTHRACIS; ENDOCYTOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LETHAL GENE; NONHUMAN; PATHOGENESIS; PHOSPHORYLATION; PROPHYLAXIS; REVIEW; TOXEMIA; VACCINATION;

EID: 84946753503     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.01009     Document Type: Review

References (71)

1. Abrami, L., Bischofberger, M., Kunz, B., Groux, R., and van der Goot, F. G. (2010). Endocytosis of the anthrax toxin is mediated by clathrin, actin and unconventional adaptors. PLoS Pathog. 6:e1000792. doi: 10.1371/journal.ppat.1000792
2. Abrami, L., Brandi, L., Moayeri, M., Brown, M. J., Krantz, B. A., Leppla, S. H., et al. (2013). Hijacking multivesicular bodies enables long-term and exosome-mediated long-distance action of anthrax toxin. Cell Rep. 5, 986-996. doi: 10.1016/j.celrep.2013.10.019
3. Abrami, L., Leppla, S. H., and van der Goot, F. G. (2006). Receptor palmitoylation and ubiquination regulate anthrax toxin endocytosis. J. Cell Biol. 172, 309-320. doi: 10.1083/jcb.200507067
4. Abrami, L., Reig, N., and van der Goot, F. G. (2005). Anthrax toxin: the long and winding road that leads to the kill. Trends Microbiol. 13, 72-78. doi: 10.1016/j.tim.2004.12.004
5. Albrecht, M. T., Li, H., Williamson, E. D., LeButt, C. S., Flick-Smith, H. C., Quinn, C. P., et al. (2007). Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun. 75, 5425-5433. doi: 10.1128/IAI.00261-07
6. Anthrax Vaccine Adsorbed. (1965). United States Patent US 3208909. Washington, DC: US Patent and Trademark Office.
7. Anthrax ACIP Vaccine Recommendations. (2001). Available online at: http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/anthrax.html
8. Ascough, S., Ingram, R. J., Chu, K. K., Reynolds, C. J., Musson, J. A., Doganay, M., et al. (2014). Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity. PLoS Pathog. 10:e1004085. doi: 10.1371/journal.ppat.1004085
9. Ascough, S. J., Ingram, R. J., and Altmann, D. M. (2012). Anthrax lethal toxin and the induction of CD4 T cell immunity. Toxins 4, 878-899. doi: 10.3390/toxins4100878
10. Baillie, L. W., Huwar, T. B., Moore, S., Mellado-Sanchez, G., Ridriguez, L., Neeson, B. N., et al. (2010). An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. Vaccine 28, 6740-6748. doi: 10.1016/j.vaccine.2010.07.075
11. Berger, T., Kassirer, M., and Aran, A. A. (2014). Injectional anthrax-new presentation of an old disease. Eurosurveillance 19, 1-11. doi: 10.2807/1560-7917.es2014.19.32.20877
12. Bielinska, A. U., Janczak, K. W., Landers, J. J., Makidon, P., Sower, L. E., Peterson, J. W., et al. (2007). Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun. 75, 4020-4029. doi: 10.1128/IAI.00070-07
13. Blankley, S., Berry, M. P. R., Graham, C. M., Bloom, C. I., Lipman, M., and O'Garra, A. (2014). The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis. Phil. Trans. R. Soc. B 369:20130427. doi: 10.1098/rstb.2013.0427
14. Boyaka, P. N., Tafaro, A., Fischer, R., Leppla, S. H., Fujihashi, K., and McGhee, J. R. (2003). Effective mucosal immunity to anthrax: neutralizingantibodies and Th cell responses following nasal immunization with protective antigen1. J. Immunol. 170, 5636-5643. doi: 10.4049/jimmunol.170.11.5636
15. Boyer, A. E., Gallegos-Candela, M., Quinn, C. P., Woolfitt, A. R., Brumlow, J. O., Isbell, K., et al. (2015). High-sensitivity MALDI-TOF MS quantification of anthrax lethal toxin for diagnostics and evaluation of medical countermeasures. Anal. Bioanal. Chem. 407, 2847-2858. doi: 10.1007/s00216-015-8509-5
16. Boyer, A. E., Quinn, C. P., Hoffmaster, A. R., Kozel, T. R., Saile, E., Marston, C. K., et al. (2009). Kinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaques. Infect. Immun. 77, 3432-3441 doi: 10.1128/IAI.00346-09
17. Boyer, A. E., Quinn, C. P., Woolfitt, A. R., Pirkle, J. L., McWilliams, L. G., Stamey, K. L., et al. (2007). Detection and quantification of anthrax lethal factor in serum by mass spectrometry. Anal. Chem. 79, 8463-8470. doi: 10.1021/ac701741s
18. Brossier, F., Levy, M., and Mock, M. (2002). Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. 70, 661-664. doi: 10.1128/IAI.70.2.661-664.2002
19. Chen, L., Schiffer, J. M., Dalton, S., Sabourin, C. L., Niemuth, N. A., Plikaytis, B. D., et al. (2014). Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques. Clin. Vaccine Immunol. 21, 1512-1520. doi: 10.1128/CVI.00469-14
20. Chen, Z., Moayeri, M., and Purcell, R. (2011). Monoclonal antibody therapies against anthrax. Toxins 3, 1004-1019. doi: 10.3390/toxins3081004
21. Ding, G., Chen, X., Xhu, J., Duesbery, N. S., Chang, X., and Cao, B. (2013). A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro. Clin. Dev. Immunol. 2013:475809. doi: 10.1155/2013/475809
22. Ezzell, J. W., Abshire, T. G., Panchal, R., Chabot, D., Bavari, S., Leffel, E. K., et al. (2009). Association of Bacillus anthracis capsule with lethal toxin during experimental infection. Infect. Immun. 77, 749-755. doi: 10.1128/IAI.00764-08
23. Fay, M. P., Follmann, D. A., Lynn, F. J., Schiffer, J. M., Stark, G. V., Kohberger, R. K., et al. (2012). Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci. Transl. Med. 4, 151ra126. doi: 10.1126/scitranslmed.3004073
24. Flick-Smith, H. C. I, Eyles, J. E., Hebdon, R., Waters, E. L., Beedham, R. J., Stagg, T. J., et al. (2002a). Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun. 70, 2022-2028. doi: 10.1128/IAI.70.4.2022-2028.2002
25. Flick-Smith, H. C. I, Walker, N. J., Gibson, P., Bullifent, H., Hayward, S., Miller, J., et al. (2002b). A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect. Immun. 70, 1653-1656. doi: 10.1128/IAI.70.3.1653-1656.2002
26. Friedlander, A. M., and Little, S. F. (2009). Advances in the development of next-generation anthrax vaccines. Vaccine 27, D28-D32. doi: 10.1016/j.vaccine.2009.08.102
27. Guichard, A., McGillivray, S. M., Cruz-Moreno, B., van Sorge, N. M., Nizet, V., and Bier, E. (2010). Anthrax toxins cooperatively inhibit endocytic recycling by the Rab11/Sec15 exocyst. Nature 467, 854-858. doi: 10.1038/nature09446
28. Guichard, A., Nizet, V., and Bier, E. (2011). New insights into the biological effects of anthrax toxins: linking cellular to organismal responses. Microb. Infect. 20, 1-22. doi: 10.1016/j.micinf.2011.08.016
29. Hepburn, M. J., Dyson, E. H., Simpson, A. J. H., Brenneman, K. E., Bailey, N., Wilkinson, L., et al. (2007). Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine. Vaccine 25, 6089-6097. doi: 10.1016/j.vaccine.2007.05.018
30. Ingram, R. J., Harris, A., Ascough, S., Metan, G., Doganay, M., Ballie, L., et al. (2013). Exposure to anthrax toxin alters human leucocyte expression of anthrax toxin receptor 1. Clin. Exp. Immunol. 173, 84-91. doi: 10.1111/cei.12090
31. Ingram, R. J., Metan, G., Maillere, B., Doganay, M., Ozkul, Y., and Kim, L. U. (2010). Natural exposure to cutaneous anthrax gives long-lasting t cell immunity encompassing infection-specific epitopes. J. Immunol. 184, 3814-3821. doi: 10.4049/jimmunol.0901581
32. Ionin, B., Hopkins, R. J., Pleune, B., Sivko, G. S., Reid, F. M., Clement, K. J., et al. (2013). Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis. Clin. Vaccine Immunol. 20, 1016-1026. doi: 10.1128/CVI.00099-13
33. Jang, J., Cho, M., Chun, J.-H., Cho, M.-H., Park, J., Oh, H.-B., et al. (2011). The poly-y-D-glutamic acid capsule of Bacillus anthracis enhances lethal toxin activity. Infect. Immun. 79, 3846-3854. doi: 10.1128/IAI.01145-10
34. Jernigan, J. A. (2001). Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7, 933-944. doi: 10.3201/eid0706.010604
35. Jernigan, J. A., Raghunathan, P., Bell, B. P., Brechner, R., Bresnitz, E. A., Butler, J. C., et al. (2002). Investigation of bioterrorism-related anthrax, United, States (2001): epidemiologic findings. Emerg. Inf. Dis. 8, 1019-1028.
36. Koch, R. (1876). Beitrage zur Biologie der Pflanzen. Breslau: Zweiter Band Zweites Heft.
37. Lacy, D. B., Wigelsworth, D. J., Melnyk, R. A., Harrison, S. C., and Collier, R. J. (2004). Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc. Natl. Acad. Sci. U.S.A. 101, 13147-13151. doi: 10.1073/pnas.0405405101
38. Leffel, E. K., Bourdage, J., Fuerst, T., Williamson, E. D., Duchars, M., and Fusco, P. (2012). rPA vaccine improves survival when administered as a post-exposure prophylaxis countermeasure with antibiotics, in the New Zealand white rabbit model of inhalation anthrax. Clin. Vaccine Immunol. 19, 1158-1164. doi: 10.1128/CVI.00240-12
39. Lim, N. K., Kim, J. H., Oh, M. S., Lee, S., Kim, S. Y., Kim, K. S., et al. (2005). An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect. Immun. 73, 6547-6551. doi: 10.1128/IAI.73.10.6547-6551.2005
40. Little, S. F., Novak, J. M., Lowe, J. R., Leppla, S. H., Singh, Y., Klimpel, K. R., et al. (1996). Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142, 707-715.
41. Liu, S., Schubert, R. L., Bugge, T. H., and Leppla, S. H. (2003). Anthrax toxin: structures, functions and tumour targeting. Expert Opin. Biol. Ther. 3, 843-853. doi: 10.1517/14712598.3.5.843
42. Malkevich, N. V., Hopkins, R. J., Bernton, E., Meister, G. T., Vela, E. B., Atiee, G., et al. (2014). Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans. Antimicrob. Agents Chemother. 58, 3618-3625. doi: 10.1128/AAC.02295-13
43. Martchenko, M., Jeong, S. Y., and Cohen, S. N. (2010). Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. Proc. Natl. Acad. Sci. U.S.A. 107, 15583-15588 doi: 10.1073/pnas.1010145107
44. Meselson, M., Guillemin, J., Hugh-Jones, M., Langmuir, A., Popova, I., Shelokov, A., et al. (1994). The Sverdlovsk anthrax outbreak of 1979. Science 266, 1202-1208. doi: 10.1126/science.7973702
45. Minang, J. T., Inglefield, J. R., Harris, A. M., Lathey, J. L., Alleva, D. G., Sweeney, D. L., et al. (2014). Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909). Vaccine 32, 6847-6854. doi: 10.1016/j.vaccine.2014.01.096
46. Moayeri, M., and Leppla, S. H. (2004). The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 7, 19-24. doi: 10.1016/j.mib.2003.12.001
47. Mohamadzadeh, M., Duong, T., Sandwick, S. J., Hoover, T., and Klaenhammer, T. R. (2009). Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc. Natl. Acad. Sci. U.S.A. 106, 4331-4336. doi: 10.1073/pnas.0900029106
48. Park, Y. S., Lee, J. H., Hung, C.-F., Wu, T.-C., and Kim, T. W. (2008). Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect. Immun. 76, 1952-1959. doi: 10.1128/IAI.01722-07
49. Perkins, B. A., Popovic, T., and Yeskey, K. (2002). Public Health in the time of bioterrorism. Emerg. Inf. Dis. 8, 1015-1018. doi: 10.3201/eid0810.020444
50. Petosa, C., Collier, R. J., Klimpel, K. R., Leppla, S. H., and Liddington, R. C. (1997). Crystal structure of the anthrax toxin protective antigen. Nature 385, 833-838. doi: 10.1038/385833a0
51. Piris-Gimenez, A., Corre, J. P., Jouvion, G., Candela, T., Khun, H., and Goosens, P. L. (2009). Encapsulated Bacillus anthracis interacts closely with liver endothelium. J. Infect. Dis. 200, 1381-1389. doi: 10.1086/644506
52. Plotkin, S., and Grabenstein, J. D. (2008). Countering anthrax vaccines and immunoglobulins. J. Infect. Dis. 46, 129-136. doi: 10.1086/523578
53. Pohl, M. A., Rivera, J., Nakouzi, A., Chow, S. K., and Casadevall, A. (2013). Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays. Infect. Immun. 81, 1880-1888. doi: 10.1128/IAI.01328-12
54. Ribot, W. J., Panchal, R. G., Brittingham, K. C., Ruthel, G., Kenny, T. A., Lane, D., et al. (2006). Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival. Infect. Immun. 74, 5029-5034. doi: 10.1128/IAI.00275-06
55. Riddle, V., Leese, P., Blanset, D., Adamcio, M., Meldorf, M., and Lowy, I. (2011). Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Vaccine Immunol. 18, 2136-2142. doi: 10.1128/CVI.05059-11
56. Ross, P. J., Sutton, C. E., Higgins, S., Allen, A. C., Walsh, K., Misiak, A., et al. (2013). Relative contribution for Th1 and Th17 cells in a adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog. 9:e1003264. doi: 10.1371/journal.ppat.1003264
57. Schiffer, J. M., Chen, L., Dalton, S., Niemuth, N. A., Sabourin, C. L., and Quinn, A. P. (2015). Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans. Vaccine 33, 3709-3716. doi: 10.1016/j.vaccine.2015.05.091
58. Shepard, C. W., Soriano-Gabarro, M., Zell, E. R., Hayslett, J., Lukacs, S., Goldstein, S., et al. (2002). Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg. Infect. Dis. 8, 1124-1132. doi: 10.3201/eid0810.020349
59. Smith, H. (2002). Dicovery of the anthrax toxins: the beginning of studies of virulence factors regulated in vivo. Int. J. Med. Microbiol. 291, 411-417. doi: 10.1078/1438-4221-00147
60. Tang, W., and Guo, Q. (2009). The adenylyl cyclase activity of anthrax edema factor. Mol. Aspects Med. 30, 423-430. doi: 10.1016/j.mam.2009.06.001
61. Thompson, I. J. T., Mann, E. R., Stokes, M. G., English, N. R., Knight, S. C., and Williamson, E. D. (2014). Specific activation of dendritic cells enhances clearance of Bacillus anthracis following Infection. PLoS ONE. 9:e109720. doi: 10.1371/journal.pone.0109720
62. Tournier, J.-N., Paccani, S. R., Quesnel-Hellmann, A., and Baldari, C. T. (2009). Anthrax toxins: a weapon to systematically dismantle the host immune defences. Mol. Aspects Med. 30, 456-466. doi: 10.1016/j.mam.2009.06.002
63. Tournier, J.-N., Quesnel-Hellmann, A., Mathieu, J., Montecucco, C., Tang, W.-J., Mock, M., et al. (2005). Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. 174, 4934-4941. doi: 10.4049/jimmunol.174.8.4934
64. Trouillon, R., Williamson, E. D., Saint, R. J., and O'Hare, D. (2012). Electrochemical detection of the binding of Bacillus anthracis protective antigen (PA) to the membrane receptor on macrophages through release of nitric oxide. Biosens. Bioelectron. 38, 138-144. doi: 10.1016/j.bios.2012.05.012
65. Turnbull, P. C. B. (1991). Anthrax vaccines, past, present and future. Vaccine 9, 533-539. doi: 10.1016/0264-410X(91)90237-Z
66. van der Goot, G., and Young, J. A. T. (2009). Receptors of anthrax toxin and cell entry. Mol. Aspects Med. 30, 406-412.
67. Wei, W., Lu, Q., Chaudry, G. J., Leppla, S. H., and Cohen, S. N. (2006). The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell 124, 1141-1154. doi: 10.1016/j.cell.2005.12.045
68. Williamson, E. D., Hodgson, I., Walker, N. J., Topping, A., Duchars, M., Mott, J., et al. (2005). Immunogenicity of recombinant Protective Antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 73, 5978-5987. doi: 10.1128/IAI.73.9.5978-5987.2005
69. World Health Organization, Food Agriculture Organization of the United Nations, World Organization for Animal Health. (2008). Anthrax in Humans and Animals, 4th Edn. Geneva: WHO Press, World Health Organization.
70. Wright, J. G., Plikaytis, B. D., Rose, C. E., Parker, S. D., Babcock, J., Keitel, W., et al. (2014). Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine 32, 1019-1028. doi: 10.1016/j.vaccine.2013.10.039
71. Wright, J. G., Quinn, C. P., Shadomy, S., and Messonnier, N. (2010). Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2000. MMWR Recomm. Rep. 59, 1-30.